Skip to main content
ADIL
NASDAQ Life Sciences

Adial's 10-Q Flags Material Weakness, Nasdaq Deficiency, and a $52M Quarterly Loss

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
9
Price
$3.98
Mkt Cap
$8.71M
52W Low
$1.31
52W High
$10.75
52W Position info
204% above low
Off High info
63% below high
Rel. Volume info
0.1× avg
Market data snapshot near publication time

ADIL has more than doubled off its 52-week low of $1.31 on light trading volume (0.1× avg).

Summary

Adial's 10-Q reveals a material weakness, Nasdaq listing deficiency, and a $52M quarterly loss, alongside a PIPE amendment and COO termination.

Updates

  1. · Reuters — Adial's Q2 loss per share of $11.25 missed consensus of $1.03, driven by a $46.2M acquired in-process R&D charge. Management expects an IND for AT177 in H1 2027 and a Phase 1a trial in H2 2027, with cash runway into H2 2027.


Key Events · Earnings and Guidance · ADIL

  • Material Weakness Disclosed

    Management identified a material weakness in internal control over financial reporting related to accounting for the Merger, Financing, and Azora Note Exchange. Disclosure controls were deemed ineffective as of June 30, 2026.

  • Nasdaq Listing Deficiency

    Stockholders' equity of -$38.4 million as of June 30, 2026 falls below Nasdaq's $2.5 million continued listing requirement. The company expects a deficiency notice and must present a compliance plan.

  • Q2 Net Loss of $52.0M

    Net loss of $52.0 million for Q2 2026 includes a $46.2 million acquired in-process R&D charge from the Azora acquisition and a $6.1 million loss on extinguishment of Azora convertible notes.

  • PIPE Amendment Lowers Price

    Amendment No. 1 to the Securities Purchase Agreement, dated August 12, 2026, reduces the Minimum Issuance Price from $4.25 to $4.00, allowing future equity sales at a lower price.


Analysis · ADIL · Life Sciences

The Q2 10-Q from Adial discloses a material weakness in internal controls over the Azora merger accounting, a Nasdaq continued listing deficiency with stockholders' equity at -$38.4 million, and a $52.0 million net loss driven by a $46.2 million acquired IPR&D charge. The company also amended its PIPE agreement to lower the minimum issuance price from $4.25 to $4.00, and terminated COO Tony Goodman. These are first-time disclosures that materially worsen the risk profile.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 52.4% of the 208 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.91%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ADIL was trading at $3.98 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.7M. The 52-week trading range was $1.31 to $10.75. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ADIL - Latest Insights

ADIL
Nov 12, 2026, 4:06 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $4.86
Real-time Price: $4.86 info
Change: $0 (0%) info
Market Cap: $13.261M info
ADIL
Nov 12, 2026, 4:05 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $4.86
Real-time Price: $4.86 info
Change: $0 (0%) info
Market Cap: $13.261M info
ADIL
Nov 09, 2026, 7:30 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $4.86
Real-time Price: $4.86 info
Change: $0 (0%) info
Market Cap: $13.261M info
ADIL
Oct 28, 2026, 5:56 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $5.08
Real-time Price: $4.86 info
Change: -$0.220 (-4%) info
Market Cap: $13.261M info
ADIL
Oct 28, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $4.86
Real-time Price: $4.86 info
Change: -$0.0036 (-0.07%) info
Market Cap: $13.261M info